What biomarkers best predict response to B-cell depleting therapies in MS?  

While no single biomarker is yet validated for routine use in predicting response to B-cell therapy in MS, CSF CXCL13, IgM OCBs, and neurofilament light chain are among the most promising. Multimodal approaches that combine imaging, clinical features, and fluid biomarkers are likely to offer the bes...